19:41 , Apr 12, 2018 |  BC Innovations  |  Translation in Brief

Shape recognition

A Cardiff University team has engineered a D-peptide that mimicked the T cell agonist activity of an influenza peptide and protected mice from infection by the virus. The findings suggest oral vaccines based on synthetic...
18:16 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mouse studies suggest a vaccine based on an M1-mimicking synthetic peptide could help treat influenza. Screening of a combinatorial library of D-peptides against CD8 + T cell clones specific for the immunodominant...
21:41 , Nov 30, 2017 |  BC Innovations  |  Strategy

Doctors in the house

While academic partnerships have become par for the course in pharma, GSK is going a step beyond the standard model of external alliances by bringing professors in-house with virtually unrestricted access to its activities. The...
03:45 , Apr 7, 2017 |  BC Innovations  |  Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc. ’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research...
22:01 , Apr 4, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Cell culture studies identified prodrugs of the PINK1 agonist kinetin riboside triphosphate that could help treat PD. The prodrugs were kinetin riboside phosphorothioate-based compounds that were cleaved by cellular esterases and...
16:12 , Mar 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Cytomegalovirus (CMV) Mouse studies suggest inhibiting CD126 could help treat CMV. In a mouse model of CMV, a mAb against mouse CD126 decreased weight loss and viral load in the spleen compared with control...
08:00 , Dec 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: V-set and immunoglobulin domain containing 4 (VSIG4); CD59; complement C5b-9 membrane attack complex (MAC)

Inflammation INDICATION: Shock / trauma In vitro and mouse studies suggest a VSIG4- CD59 fusion protein could help treat traumatic brain injury (TBI). In vitro, dimers of the VSIG4-CD59 fusion protein bound complement 3b (C3b)...
08:00 , Nov 12, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Tool compounds for probing cyclin dependent kinase 8 (CDK8)- and cyclin dependent kinase 19 (CDK19; CDC2L6)-dependent tumor growth

CDK8 CDK19 cyclin dependent kinase 8 cyclin dependent kinase 19 CDC2L6 Cardiff University Merck Serono S.A. Merck KGaA The Institute of Cancer Research...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Company News

Cardiff University, Tiziana Life Sciences deal

The university granted Tiziana exclusive, worldwide rights to small molecule OH14 . Tiziana plans to develop the preclinical cellular FLICE-like inhibitory protein (c-FLIP) inhibitor for cancer. The company plans to start clinical testing of OH14...
07:00 , Jun 11, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Copy number variations in GABA A receptors as risk markers for schizophrenia

Biomarkers TECHNOLOGY: Gene profiling Genetic studies suggest copy number variations in GABA A receptors could help predict the risk of schizophrenia. A genetic association study in 11,355 schizophrenia cases and 16,416 controls identified an association...